{"pmid":32383254,"title":"Evaluation of SARS-CoV-2 neutralizing antibodies using of a CPE-based Colorimetric live virus micro-neutralization assay in human serum samples.","text":["Evaluation of SARS-CoV-2 neutralizing antibodies using of a CPE-based Colorimetric live virus micro-neutralization assay in human serum samples.","The micro-neutralization assay is a fundamental test in virology, immunology, vaccine assessment and epidemiology studies. Since the SARS-CoV-2 outbreak at the end of December 2019 in China, it has become extremely important to have well-established and validated diagnostic and serological assays for this new emerging virus. Here, we present a micro-neutralization assay with the use of SARS-CoV-2 wild type virus with two different methods of read-out. We evaluated the performance of this assay using human serum samples taken from an italian seroepidemiological study being performed at the University of Siena, along with the human monoclonal antibody CR3022 and some iper-immune animal serum samples against Influenza and Adenovirus strains. The same panel of human samples have been previously tested in ELISA as a pre-screening. Positive, borderline and negative ELISA samples were evaluated in neutralization assay using two different method of read-out: subjective (by means of an inverted optical microscope) and objective (by means of a spectrophotometer). Our findings suggest that at least 50% of positive ELISA samples are positive in neutralization as well, and that method is able to quantify different antibody concentrations in a specific manner. Taken together, our results confirm that the colorimetric cytopathic effect-based microneutralization assay could be used as a valid clinical test method for epidemiological and vaccines studies. This article is protected by copyright. All rights reserved.","J Med Virol","Manenti, Alessandro","Maggetti, Marta","Casa, Elisa","Martinuzzi, Donata","Torelli, Alessandro","Trombetta, Claudia M","Marchi, Serena","Montomoli, Emanuele","32383254"],"abstract":["The micro-neutralization assay is a fundamental test in virology, immunology, vaccine assessment and epidemiology studies. Since the SARS-CoV-2 outbreak at the end of December 2019 in China, it has become extremely important to have well-established and validated diagnostic and serological assays for this new emerging virus. Here, we present a micro-neutralization assay with the use of SARS-CoV-2 wild type virus with two different methods of read-out. We evaluated the performance of this assay using human serum samples taken from an italian seroepidemiological study being performed at the University of Siena, along with the human monoclonal antibody CR3022 and some iper-immune animal serum samples against Influenza and Adenovirus strains. The same panel of human samples have been previously tested in ELISA as a pre-screening. Positive, borderline and negative ELISA samples were evaluated in neutralization assay using two different method of read-out: subjective (by means of an inverted optical microscope) and objective (by means of a spectrophotometer). Our findings suggest that at least 50% of positive ELISA samples are positive in neutralization as well, and that method is able to quantify different antibody concentrations in a specific manner. Taken together, our results confirm that the colorimetric cytopathic effect-based microneutralization assay could be used as a valid clinical test method for epidemiological and vaccines studies. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Manenti, Alessandro","Maggetti, Marta","Casa, Elisa","Martinuzzi, Donata","Torelli, Alessandro","Trombetta, Claudia M","Marchi, Serena","Montomoli, Emanuele"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383254","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25986","keywords":["neutralization","sars coronavirus","epidemiology","humoral immunity","pandemic"],"locations":["China","italian"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1666419683388030977,"score":9.490897,"similar":[{"pmid":32267220,"title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","text":["Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.","Emerg Infect Dis","Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L","32267220"],"abstract":["A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies."],"journal":"Emerg Infect Dis","authors":["Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267220","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3201/eid2607.200841","keywords":["covid-19","elisa","hcov","rbd","sars-cov-2","severe acute respiratory syndrome coronavirus 2","antibodies","coronavirus","coronavirus disease 2019","human coronavirus","neutralization","nucleocapsid protein","receptor-binding domain","respiratory infections","serologic analysis","spike protein","viruses","zoonoses"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491931590658,"score":379.97122},{"pmid":32207377,"pmcid":"PMC7144318","title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","text":["Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.","Emerg Microbes Infect","Nie, Jianhui","Li, Qianqian","Wu, Jiajing","Zhao, Chenyan","Hao, Huan","Liu, Huan","Zhang, Li","Nie, Lingling","Qin, Haiyang","Wang, Meng","Lu, Qiong","Li, Xiaoyu","Sun, Qiyu","Liu, Junkai","Fan, Changfa","Huang, Weijin","Xu, Miao","Wang, Youchun","32207377"],"abstract":["Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus."],"journal":"Emerg Microbes Infect","authors":["Nie, Jianhui","Li, Qianqian","Wu, Jiajing","Zhao, Chenyan","Hao, Huan","Liu, Huan","Zhang, Li","Nie, Lingling","Qin, Haiyang","Wang, Meng","Lu, Qiong","Li, Xiaoyu","Sun, Qiyu","Liu, Junkai","Fan, Changfa","Huang, Weijin","Xu, Miao","Wang, Youchun"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32207377","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1080/22221751.2020.1743767","keywords":["covid-19","sars-cov-2","neutralization assay","neutralizing antibody","pseudovirus"],"locations":["pseudovirus","pseudovirus"],"topics":["Treatment"],"weight":1,"_version_":1666138490189905920,"score":321.35962},{"pmid":32485620,"title":"Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies.","text":["Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies.","As the Coronavirus 2019 (COVID-19) pandemic evolves, the development of immunoassays to help determine exposure and potentially predict immunity has become a pressing priority. In this report we present the performance of the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen. Specimens from patients, with and without COVID-19 infection, were tested at the University of Chicago Clinical Microbiology and Immunology Laboratory. Of 86 samples from SARS-CoV-2 PCR-negative patients, including 28 samples positive for common human coronavirus strains, 76 tested negative and 10 tested positive for IgA (88.4% agreement, 95% CI: 79.9-93.6) while 84 tested negative and 2 tested positive for IgG (97.7% agreement, 95% CI: 91.9-99.6). Of 82 samples from SARS-CoV-2 PCR-positive patients, 14 tested negative and 68 tested positive for IgA (82.9% agreement, 95% CI: 73.4-89.5) while 27 tested negative and 55 tested positive for IgG (67.1% agreement, 95% CI: 56.3-76.3). Of samples collected >/=4 days after positive PCR, 38 of 42 (90.5% agreement, 95% CI: 77.9-96.2) were positive for IgA, and 42 of 42 (100% agreement, 95% CI: 91.6-100) were positive for IgG, respectively. The EUROIMMUN Anti-SARS-CoV-2 ELISA Assay demonstrated good sensitivity for detection of IgA and excellent sensitivity for detection of IgG antibodies from samples collected >/=4 days, after COVID-19 diagnosis by PCR. This assay demonstrated good specificity for IgA and excellent specificity for IgG and demonstrated only borderline cross reaction in 2 of the 28 samples from patients with common human coronaviruses infection, types NL63 and OC43.","J Clin Virol","Beavis, Kathleen G","Matushek, Scott M","Abeleda, Ana Precy F","Bethel, Cindy","Hunt, Carlissa","Gillen, Stephanie","Moran, Angelica","Tesic, Vera","32485620"],"abstract":["As the Coronavirus 2019 (COVID-19) pandemic evolves, the development of immunoassays to help determine exposure and potentially predict immunity has become a pressing priority. In this report we present the performance of the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen. Specimens from patients, with and without COVID-19 infection, were tested at the University of Chicago Clinical Microbiology and Immunology Laboratory. Of 86 samples from SARS-CoV-2 PCR-negative patients, including 28 samples positive for common human coronavirus strains, 76 tested negative and 10 tested positive for IgA (88.4% agreement, 95% CI: 79.9-93.6) while 84 tested negative and 2 tested positive for IgG (97.7% agreement, 95% CI: 91.9-99.6). Of 82 samples from SARS-CoV-2 PCR-positive patients, 14 tested negative and 68 tested positive for IgA (82.9% agreement, 95% CI: 73.4-89.5) while 27 tested negative and 55 tested positive for IgG (67.1% agreement, 95% CI: 56.3-76.3). Of samples collected >/=4 days after positive PCR, 38 of 42 (90.5% agreement, 95% CI: 77.9-96.2) were positive for IgA, and 42 of 42 (100% agreement, 95% CI: 91.6-100) were positive for IgG, respectively. The EUROIMMUN Anti-SARS-CoV-2 ELISA Assay demonstrated good sensitivity for detection of IgA and excellent sensitivity for detection of IgG antibodies from samples collected >/=4 days, after COVID-19 diagnosis by PCR. This assay demonstrated good specificity for IgA and excellent specificity for IgG and demonstrated only borderline cross reaction in 2 of the 28 samples from patients with common human coronaviruses infection, types NL63 and OC43."],"journal":"J Clin Virol","authors":["Beavis, Kathleen G","Matushek, Scott M","Abeleda, Ana Precy F","Bethel, Cindy","Hunt, Carlissa","Gillen, Stephanie","Moran, Angelica","Tesic, Vera"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485620","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jcv.2020.104468","keywords":["covid-19","sars-cov-2","serology"],"topics":["Diagnosis"],"weight":1,"_version_":1668532114790809600,"score":282.39404},{"pmid":32302069,"title":"SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.","text":["SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.","In late 2019, cases of atypical pneumonia were detected in China. The etiological agent was quickly identified as a betacoronavirus (named SARS-CoV-2), which has since caused a pandemic. Several methods allowing for the specific detection of viral nucleic acids have been established, but these only allow detection of the virus during a short period of time, generally during acute infection. Serological assays are urgently needed to conduct serosurveys, to understand the antibody responses mounted in response to the virus, and to identify individuals who are potentially immune to re-infection. Here we describe a detailed protocol for expression of antigens derived from the spike protein of SARS-CoV-2 that can serve as a substrate for immunological assays, as well as a two-stage serological enzyme-linked immunosorbent assay (ELISA). These assays can be used for research studies and for testing in clinical laboratories. (c) 2020 The Authors. Basic Protocol 1: Mammalian cell transfection and protein purification Basic Protocol 2: A two-stage ELISA for high-throughput screening of human serum samples for antibodies binding to the spike protein of SARS-CoV-2.","Curr Protoc Microbiol","Stadlbauer, Daniel","Amanat, Fatima","Chromikova, Veronika","Jiang, Kaijun","Strohmeier, Shirin","Arunkumar, Guha Asthagiri","Tan, Jessica","Bhavsar, Disha","Capuano, Christina","Kirkpatrick, Ericka","Meade, Philip","Brito, Ruhi Nichalle","Teo, Catherine","McMahon, Meagan","Simon, Viviana","Krammer, Florian","32302069"],"abstract":["In late 2019, cases of atypical pneumonia were detected in China. The etiological agent was quickly identified as a betacoronavirus (named SARS-CoV-2), which has since caused a pandemic. Several methods allowing for the specific detection of viral nucleic acids have been established, but these only allow detection of the virus during a short period of time, generally during acute infection. Serological assays are urgently needed to conduct serosurveys, to understand the antibody responses mounted in response to the virus, and to identify individuals who are potentially immune to re-infection. Here we describe a detailed protocol for expression of antigens derived from the spike protein of SARS-CoV-2 that can serve as a substrate for immunological assays, as well as a two-stage serological enzyme-linked immunosorbent assay (ELISA). These assays can be used for research studies and for testing in clinical laboratories. (c) 2020 The Authors. Basic Protocol 1: Mammalian cell transfection and protein purification Basic Protocol 2: A two-stage ELISA for high-throughput screening of human serum samples for antibodies binding to the spike protein of SARS-CoV-2."],"journal":"Curr Protoc Microbiol","authors":["Stadlbauer, Daniel","Amanat, Fatima","Chromikova, Veronika","Jiang, Kaijun","Strohmeier, Shirin","Arunkumar, Guha Asthagiri","Tan, Jessica","Bhavsar, Disha","Capuano, Christina","Kirkpatrick, Ericka","Meade, Philip","Brito, Ruhi Nichalle","Teo, Catherine","McMahon, Meagan","Simon, Viviana","Krammer, Florian"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302069","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/cpmc.100","keywords":["covid19","elisa","sars-cov-2","protein expression","serological assay"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138494890672128,"score":270.76694},{"pmid":32504735,"title":"Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.","text":["Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.","OBJECTIVES: SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. METHODS: In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA. RESULTS: Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell(R) POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon). CONCLUSIONS: The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.","J Infect","Tuaillon, E","Bollore, K","Pisoni, A","Debiesse, S","Renault, C","S, Marie","S, Groc","C, Niels","N, Pansu","Am, Dupuy","D, Morquin","V, Foulongne","A, Bourdin","V, Le Moing","P, Van de Perre","32504735"],"abstract":["OBJECTIVES: SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. METHODS: In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA. RESULTS: Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell(R) POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon). CONCLUSIONS: The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved."],"journal":"J Infect","authors":["Tuaillon, E","Bollore, K","Pisoni, A","Debiesse, S","Renault, C","S, Marie","S, Groc","C, Niels","N, Pansu","Am, Dupuy","D, Morquin","V, Foulongne","A, Bourdin","V, Le Moing","P, Van de Perre"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504735","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.077","keywords":["covid-19","elisa","sars-cov-2 antibodies","point of care tests"],"topics":["Diagnosis"],"weight":1,"_version_":1668892488220278784,"score":263.64984}]}